Article title: Strategic Development of AZD1775, a Wee1 Kinase Inhibitor, for Cancer Therapy
Authors: Fu, S., Wang, Y, Keyomarsi, K, et al.
Journal: Expert Opinion on Investigational Drugs
Bibliometrics: Volume 27, Number 09, pages 741 - 751
DOI: http://dx.doi.org/10.1080/13543784.2018.1511700
When this article was first published online there was an error in the author name. Also, a declaration of interest was missed. These are given below
1. The last author name should be “Funda Meric-Bernstam”
2. Declaration of Interest is given below
F. Meric-Bernstam reports grants from Novartis, AstraZeneca, Calithera, Bayer, Jounce, CytoMx, eFFECTOR, Zymeworks, PUMA Biotechnology, Curis, Millennium, Daiichi Sankyo, Abbvie, Guardant Health, and Takeda as well as grants and travel related fees from Taiho, Genentech, Debiopharm Group, and Pfizer. She also served as a consultant to Pieris, Dialectica, Sumitomo Dainippon, Samsung Bioepis, Aduro, OrigiMed, Xencor, and Jackson Laboratory, and advisor to Inflection Biosciences, GRAIL, Darwin Health, Clearlight Diagnostics, Spectrum, and Mersana.